Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
Titel:
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
Auteur:
Campone, Mario Im, Seock-Ah Iwata, Hiroji Clemons, Mark Ito, Yoshinori Awada, Ahmad Chia, Stephen Jagiełło-Gruszfeld, Agnieszka Pistilli, Barbara Tseng, Ling-Ming Hurvitz, Sara Masuda, Norikazu Cortés, Javier De Laurentiis, Michele Arteaga, Carlos L. Jiang, Zefei Jonat, Walter Le Mouhaër, Sylvie Sankaran, Banu Bourdeau, Laurence El-Hashimy, Mona Sellami, Dalila Baselga, José